Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure is a rapidly growing oncology company with a promising pipeline and key technologies, such as TTFields devices and Optune, that have shown strong potential for the treatment of various solid tumor cancers. While there are risks associated with clinical failures and slower sales/adoption of their products, potential M&A activity and clinical de-risking could lead to upside potential. Our neutral rating and $18 price target are based on a sum-of-parts valuation that factors in the company's current sales and royalties, as well as a discounted multiple for their pipeline products in different indications.

Bears say

NovoCure is projected to have a low-to-mid single-digit growth in GBM, with modest contributions from lung and pancreatic indications. However, there are concerns about limited adoption of Optune Lua in NSCLC and modest near-term contributions from Optune PAX in pancreatic cancer due to competition, reimbursement timelines, and modest survival benefits. This, coupled with potential risks and downside factors such as poor sales/adoption and clinical failures, lead us to have a negative outlook on the stock.

Novocure (NVCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 7 analysts, Novocure (NVCR) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.